The Spectra Optia Apheresis System (Terumo BCT) is an apheresis and cell collection platform which can be used in the treatment of sickle cell disease. The purpose of this evaluation is to assess the ...
LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT announced today that the Spectra Optia system mononuclear cell (MNC) collection protocol is now cleared by the U.S. Food and Drug Administration (FDA) and ...
Adopting Spectra Optia is claimed to have a range of system benefits (see section 2.4). Published evidence was presented on procedure times and treatment intervals (see section 3.16) but not on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results